magnolol has been researched along with Pulmonary Arterial Remodeling in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, MY; Jiang, YP; Li, T; Liu, B; Liu, S; Luo, FM; Peng, J; Wang, EL; Xiao, XH | 1 |
| Arnold, C; Hecker, M; Korff, T; Kuk, H; Meyer, R | 1 |
2 other study(ies) available for magnolol and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Magnolol alleviates hypoxia-induced pulmonary vascular remodeling through inhibition of phenotypic transformation in pulmonary arterial smooth muscle cells.
Topics: Animals; Biphenyl Compounds; Cell Proliferation; Cells, Cultured; Hypertension, Pulmonary; Hypoxia; Lignans; Myocytes, Smooth Muscle; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Vascular Remodeling | 2022 |
Magnolol inhibits venous remodeling in mice.
Topics: Animals; Antioxidants; Biphenyl Compounds; Cell Proliferation; Cells, Cultured; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Lignans; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mice; Reactive Oxygen Species; Signal Transduction; Vascular Remodeling; Veins; Venous Pressure | 2017 |